Ard van Veelen

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Helicobacter Pylori Infection

Simultaneous Determination

Ultra High Performance Liquid Chromatography

Liquid Chromatography Tandem Mass Spectrometry

Top Venues

Biomedical chromatography : BMC

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Marjon V Verschueren, Talitha Dijs, Judith L Gulikers, Ard van Veelen, Sander Croes, Lizza E L Hendriks, Adrianus Aj Smit, Lourens T Bloem, Antoine C G Egberts, Ewoudt M W van de Garde, Bas Jm Peters
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results. Immunotherapy (2023)
Ard van Veelen, G D Marijn Veerman, Marjon V Verschueren, Judith L Gulikers, Christi M J Steendam, Anita J W M Brouns, Safiye Dursun, Marthe S Paats, Vivianne C G Tjan-Heijnen, Cor van der Leest, Anne-Marie C Dingemans, Ron H J Mathijssen, Ewoudt M W van de Garde, Patrick Souverein, Johanna H M Driessen, Lizza E L Hendriks, Robin M J M van Geel, Sander Croes
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer. International journal of cancer (2023)
Ard van Veelen, Robin van Geel, Roy Schoufs, Yvo de Beer, Leo M Stolk, Lizza E L Hendriks, Sander Croes
Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomedical chromatography : BMC 35 (12) (2021)
Ard van Veelen, Robin van Geel, Yvo de Beer, Anne-Marie Dingemans, Leo Stolk, Rob Ter Heine, Frank de Vries, Sander Croes
Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomedical chromatography : BMC 34 (4) (2020)